- Home
- DEA vs BBNX Comparison
DEA vs BBNX Comparison
Compare DEA & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- BBNX
- Stock Information
- Founded
- DEA 2011
- BBNX 2015
- Country
- DEA United States
- BBNX United States
- Employees
- DEA N/A
- BBNX N/A
- Industry
- DEA Real Estate Investment Trusts
- BBNX Medical/Dental Instruments
- Sector
- DEA Real Estate
- BBNX Health Care
- Exchange
- DEA Nasdaq
- BBNX Nasdaq
- Market Cap
- DEA 912.0M
- BBNX 841.5M
- IPO Year
- DEA 2015
- BBNX 2025
- Fundamental
- Price
- DEA $22.02
- BBNX $14.77
- Analyst Decision
- DEA Hold
- BBNX Strong Buy
- Analyst Count
- DEA 4
- BBNX 10
- Target Price
- DEA $27.69
- BBNX $25.20
- AVG Volume (30 Days)
- DEA 518.9K
- BBNX 523.6K
- Earning Date
- DEA 07-30-2025
- BBNX 08-06-2025
- Dividend Yield
- DEA 8.21%
- BBNX N/A
- EPS Growth
- DEA N/A
- BBNX N/A
- EPS
- DEA 0.41
- BBNX N/A
- Revenue
- DEA $314,385,000.00
- BBNX $69,830,000.00
- Revenue This Year
- DEA $7.80
- BBNX $32.79
- Revenue Next Year
- DEA $8.44
- BBNX $36.59
- P/E Ratio
- DEA $53.61
- BBNX N/A
- Revenue Growth
- DEA 6.82
- BBNX 38911.17
- 52 Week Low
- DEA $19.33
- BBNX $8.89
- 52 Week High
- DEA $36.31
- BBNX $24.50
- Technical
- Relative Strength Index (RSI)
- DEA 46.44
- BBNX N/A
- Support Level
- DEA $22.11
- BBNX N/A
- Resistance Level
- DEA $22.88
- BBNX N/A
- Average True Range (ATR)
- DEA 0.54
- BBNX 0.00
- MACD
- DEA -0.08
- BBNX 0.00
- Stochastic Oscillator
- DEA 23.87
- BBNX 0.00
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.